Alzheimer's disease

Qynapse to present clinical results of QyScore® for Alzheimer's Disease and Multiple Sclerosis at the 7th Congress of the European Academy of Neurology

Tuesday, June 15, 2021 - 11:00am

QyScore integrates an automated comparison of patient results with a large normative dataset of healthy controls, supporting faster clinical decisions, timely diagnosis and precise monitoring of Alzheimer's disease, multiple sclerosis, Parkinson's disease and other neurological disorders.

Key Points: 
  • QyScore integrates an automated comparison of patient results with a large normative dataset of healthy controls, supporting faster clinical decisions, timely diagnosis and precise monitoring of Alzheimer's disease, multiple sclerosis, Parkinson's disease and other neurological disorders.
  • At the EAN Congress, Enrica Cavedo, PhD, Scientific Lead at Qynapse, will give an ePresentation titled, "Diagnostic Accuracy of QyScore MRI Markers in the Clinical Spectrum of Alzheimer's Disease" on June 20, 2021, at 6:05 a.m.
  • Additionally, Philippe Tran, R&D Scientist at Qynapse, will give an ePoster titled, "Brain Volumes Alterations in Multiple Sclerosis Patients: Comparison to QyScore Normative Data" on June 20, 2021, at 1:30 p.m.
  • "We are pleased to present new data on QyScore at the EAN Congress, which are showing its clinical value for the diagnosis and assessment of disease progression for multiple sclerosis, mild cognitive impairment and Alzheimer's disease patients," said Olivier Courrges, CEO of Qynapse.

Qynapse to present clinical results of QyScore® for Alzheimer's Disease and Multiple Sclerosis at the 7th Congress of the European Academy of Neurology

Tuesday, June 15, 2021 - 11:00am

QyScore integrates an automated comparison of patient results with a large normative dataset of healthy controls, supporting faster clinical decisions, timely diagnosis and precise monitoring of Alzheimer's disease, multiple sclerosis, Parkinson's disease and other neurological disorders.

Key Points: 
  • QyScore integrates an automated comparison of patient results with a large normative dataset of healthy controls, supporting faster clinical decisions, timely diagnosis and precise monitoring of Alzheimer's disease, multiple sclerosis, Parkinson's disease and other neurological disorders.
  • At the EAN Congress, Enrica Cavedo, PhD, Scientific Lead at Qynapse, will give an ePresentation titled, "Diagnostic Accuracy of QyScore MRI Markers in the Clinical Spectrum of Alzheimer's Disease" on June 20, 2021, at 6:05 a.m.
  • Additionally, Philippe Tran, R&D Scientist at Qynapse, will give an ePoster titled, "Brain Volumes Alterations in Multiple Sclerosis Patients: Comparison to QyScore Normative Data" on June 20, 2021, at 1:30 p.m.
  • "We are pleased to present new data on QyScore at the EAN Congress, which are showing its clinical value for the diagnosis and assessment of disease progression for multiple sclerosis, mild cognitive impairment and Alzheimer's disease patients," said Olivier Courrges, CEO of Qynapse.

New Treatment Stops Progression of Alzheimer's Disease in Monkey Brains

Tuesday, June 15, 2021 - 5:01am

This nerve fiber protein can destroy neighboring tissue when disease-related changes to its chemical structure causes it to catch on other cells.

Key Points: 
  • This nerve fiber protein can destroy neighboring tissue when disease-related changes to its chemical structure causes it to catch on other cells.
  • The investigators say the treatment led to cognitive benefits as well.
  • Alzheimer's disease is the sixth leading cause of death in the United States and has no known cure.
  • Further testing on younger animals, she notes, would allow them to assess the effectiveness of the treatment in earlier stages of the disease.

Cognito Therapeutics Initiates Studies in Down Syndrome Associated Alzheimer’s Disease

Monday, June 14, 2021 - 1:00pm

Cognito Therapeutics , a clinical-stage company leading the development of a new class of disease-modifying digital therapeutics to treat neurodegenerative disorders including Alzheimers disease, announced today its plans to add a second digital therapeutic to the companys pipeline, initiating a new study evaluating digital therapeutic for individuals who have the genetic rare disease, Down syndrome associated Alzheimers Disease (DS-AD).

Key Points: 
  • Cognito Therapeutics , a clinical-stage company leading the development of a new class of disease-modifying digital therapeutics to treat neurodegenerative disorders including Alzheimers disease, announced today its plans to add a second digital therapeutic to the companys pipeline, initiating a new study evaluating digital therapeutic for individuals who have the genetic rare disease, Down syndrome associated Alzheimers Disease (DS-AD).
  • Roughly half of the participants with Down syndrome indicated having symptoms of cognitive decline associated with Alzheimers disease or had a confirmed diagnosis.
  • Down Syndrome associated Alzheimers Disease is a genetically associated, aggressive form of Alzheimers where individuals with Down syndrome are born with an extra copy of chromosome 21, which carries a gene that produces a specific protein called amyloid precursor protein (APP).
  • Cognito Therapeutics is a clinical-stage company developing a pipeline of disease-modifying digital therapeutics that have shown drug-like effects to treat neurodegenerative disorders including Alzheimers disease.

Anavex Life Sciences Reports New Publication in Medical Journal Elucidating the Mechanism of ANAVEX®2-73 (blarcamesine) and ANAVEX®3-71 (AF710B) related to the Treatment of Alzheimer's Disease

Monday, June 14, 2021 - 12:00pm

The publication explains that AD is a multifactorial disease, where several pathways interlink with each other and cause cognitive impairments.

Key Points: 
  • The publication explains that AD is a multifactorial disease, where several pathways interlink with each other and cause cognitive impairments.
  • The available drugs only tend to target a single pathway and mitigate the symptoms of AD without slowing the disease progression.
  • Combinatorial therapy has been suggested as a treatment strategy; however, the existence of drug-drug interaction is a concern.
  • Anavex Life Sciences product portfolio platform includes small molecule drug lead candidate ANAVEX2-73 for the treatment of Alzheimers disease, Parkinsons disease and Rett syndrome and ANAVEX3-71 for frontotemporal dementia.

Alzheimer's Association Statement: Next Steps For New Alzheimer's Treatment

Saturday, June 12, 2021 - 6:38pm

Alzheimer's Association's research experts and advisors are deeply familiar with the basic and regulatory science that led to the FDA's decision.

Key Points: 
  • Alzheimer's Association's research experts and advisors are deeply familiar with the basic and regulatory science that led to the FDA's decision.
  • Additionally, the FDA appropriately took into account the vast unmet need of the Alzheimer's community.
  • Aduhelm is certainly not a cure, but at long last it provides many with Alzheimer's disease and their families an effective treatment.
  • Our focus has and will continue to be access to this treatment for all likely to benefit.

Introducing Our FDA Designated Breakthrough: BrainSee Enterprise Software for Prognostic Measurement after aMCI Diagnosis

Thursday, June 10, 2021 - 11:41pm

Darmiyan is pleased to announce that the company's first product BrainSee has obtained from the FDA a breakthrough designation granted for innovative medical devices.

Key Points: 
  • Darmiyan is pleased to announce that the company's first product BrainSee has obtained from the FDA a breakthrough designation granted for innovative medical devices.
  • Through the breakthrough program FDA separately discerned BrainSee offers a distinct advantage over existing interventions in addressing and assessing debilitating or life-threatening diseases.
  • Darmiyan's BrainSee enterprise software offers a prognostic measurement re: Alzheimer's disease based on brain MRI and cognitive assessments after an aMCI diagnosis, which may be especially useful as you consider the opportunity offered by the newly approved Aduhelm.
  • Darmiyan's proprietary technology using brain MRI is patented in the US; patents are pending in Europe, Japan and China.

Prothena to Participate in JMP Securities Life Sciences Conference on June 16

Thursday, June 10, 2021 - 7:18pm

Following the live presentation, a replay of the webcast will be available on the Company's website for at least 90 days following the presentation date.

Key Points: 
  • Following the live presentation, a replay of the webcast will be available on the Company's website for at least 90 days following the presentation date.
  • Prothena Corporation plc is a late-stage clinical company with a robust pipeline of novel investigational therapeutics, built on protein dysregulation expertise, with the potential to change the course of devastating rare peripheral amyloid and neurodegenerative diseases.
  • Prothenas pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimers disease, Parkinsons disease and a number of other neurodegenerative diseases.
  • For more information, please visit the Companys website at www.prothena.com and follow the Company on Twitter @ProthenaCorp.

DGAP-News: Axon Neuroscience to Present at 2021 BIO Digital

Thursday, June 10, 2021 - 12:06pm

NEW YORK, NY / ACCESSWIRE / June 10, 2021 / AXON NEUROSCIENCE SE & AXON COVIDAX a. s. (together "Axon"), clinical stage biotech company in the field of Alzheimer's disease with first-in-man tau vaccine AADvac1 announced today that it will deliver a company presentation at the biotech event BIO Digital scheduled June 10-11 & 14-18, 2021.

Key Points: 
  • NEW YORK, NY / ACCESSWIRE / June 10, 2021 / AXON NEUROSCIENCE SE & AXON COVIDAX a. s. (together "Axon"), clinical stage biotech company in the field of Alzheimer's disease with first-in-man tau vaccine AADvac1 announced today that it will deliver a company presentation at the biotech event BIO Digital scheduled June 10-11 & 14-18, 2021.
  • Michal Fresser, CEO of Axon Neuroscience: "We are delighted to be able to present our COVID-19 program at BIO Digital.
  • Attendees at BIO Digital will be able to view Axon's Company Presentation before live meetings in the BIO One-on-One Partnering(TM) system begin on June 14.
  • To meet Axon at BIO Digital, you can find registration information here .

Biogen and Eisai launch initiatives to help patients with Alzheimer's disease access ADUHELM

Tuesday, June 8, 2021 - 6:09am

These initiatives aim to help patients and their families understand the disease, navigate the diagnostic journey, secure culturally competent care and afford treatment.

Key Points: 
  • These initiatives aim to help patients and their families understand the disease, navigate the diagnostic journey, secure culturally competent care and afford treatment.
  • Biogen and Eisai have also established a program with Labcorp and Mayo Clinic Laboratories to help physicians and patients access cerebrospinal fluid (CSF) diagnostic laboratory testing to aid in the diagnosis of Alzheimer's disease.
  • Biogen and Eisai are committed to addressing health equity for underserved and underrepresented populations that are at higher risk for Alzheimer's disease.
  • Biogen and Eisai are committed to providing access to ADUHELM for patients across a spectrum of financial situations.